TABLE 1.
Baseline characteristics of patients receiving rivaroxaban 15 and 20 mg daily.
| Rivaroxaban 15 mg (n = 24) | Rivaroxaban 20 mg (n = 68) | p-value | Overall (n = 92) | ||
|---|---|---|---|---|---|
| Demographic information | |||||
| Sex (male) (%) | 10 (41.7) | 47 (69.1) | 57 (62.0) | ||
| Age, years old, mean (range) | 75.46 (60-86) | 68.3 (39-95) | 0.002 | 70.2 (39-95) | |
| CHADS2 (mean±SD) | 2.17 ± 1.13 | 1.29 ± 1.13 | <0.001 | 1.52 ± 1.19 | |
| Stages of chronic kidney disease (%) | 1 | 0 (0) | 10 (14.7) | — | 10 (11.0) |
| 2 | 9 (34.6) | 44 (64.7) | — | 53 (56.7) | |
| 3 | 15 (57.7) | 14 (20.6) | — | 29 (31.6) | |
| Laboratory parameters | |||||
| eGFR by MDRD equation (ml/min/1.73m2), mean (range) | 54.33 (31-88) | 74.03 (41 to >90) | <0.001 | 68.63 (31 to >90) | |
| eGFR by Cockcroft-Gault formula (ml/min/1.73m2), mean (range) | 45.10 (23-75) | 66.17 (29 to >90) | <0.001 | 60.68 (23 to >90) | |
| eGFR <50 ml/min/1.73m2 by MDRD equation (%) | 11 (45.8) | 4 (5.9) | 0.001 | 15 (16.3) | |
| eGFR <50 ml/min/1.73m2 by Cockcroft-Gault formula (%) | 15 (62.5) | 22 (32.4) | 0.004 | 37 (40.2) | |
| Creatinine (µmol/L), mean (range) | 104.21 (62-186) | 86.85 (51-141) | 0.002 | 91.38 (51-186) | |
| PT (s), mean (range) | 12.8 (10.6-15.4) | 12.3 (10.5-19.5) | 0.113 | 12.4 (10.5-19.5) | |
| APTT (s), mean (range) | 31.5 (23.8-35.9) | 31.5 (26.4-46.4) | 0.987 | 31.4 (23.8-46.4) | |
| Medical comorbidity (%) | |||||
| Diabetes mellitus (%) | 11 (45.8) | 19 (27.9) | 0.089 | 30 (32.6) | |
| Hypertension (%) | 20 (83.3) | 41 (60.3) | 0.047 | 61 (66.3) | |
| Hyperlipidemia (%) | 9 (37.5) | 13 (19.1) | 0.095 | 22 (23.91) | |
| Ischemic heart disease (%) | 2 (8.33) | 7 (13.2) | 1.000 | 9 (9.78) | |
| Old stroke/cerebrovascular accidents (%) | 3 (12.5) | 7 (10.3) | 0.720 | 10 (10.9) | |
| Past history of cancer (%) | 4 (16.7) | 8 (11.8) | 0.726 | 12 (13.0) | |
| Causes of chronic kidney impairment | |||||
| Diabetic nephropathy (%) | 8 (53.3) | 5 (35.7) | — | 13 (44.8) | |
| Hypertensive nephropathy (%) | 6 (40.0) | 4 (28.6) | — | 10 (34.5) | |
| Unknown cause (%) | 1 (6.67) | 5 (35.7) | — | 6 (20.7) | |
| Indications of rivaroxaban | — | — | — | — | |
| Atrial fibrillation | 24 (100) | 68 (100) | — | 92 (100) | |